中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

85 records (took 0.027 seconds)

    Humanized antibodies against Globo H and uses thereof in cancer treatments
    42.
    发明授权
    Humanized antibodies against Globo H and uses thereof in cancer treatments 有权

    公开(公告)号：US10781265B2

    公开(公告)日：2020-09-22

    申请号：US15988875

    申请日：2018-05-24

    Applicant: Development Center for Biotechnology

    Inventor： Chia-Cheng Wu ,  Szu-Liang Lai ,  Yu-Jung Chen ,  Chih-Yung Hu ,  Tzu-Yin Lin

    IPC: C07K16/34

    Abstract: A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX′SGNRRYZLV (SEQ ID NO:7, wherein X′ is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

    Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
    50.
    发明授权
    Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy 有权
    人源化α-烯醇酶特异性抗体及其在癌症治疗中的应用方法

    公开(公告)号：US09527922B2

    公开(公告)日：2016-12-27

    申请号：US14588212

    申请日：2014-12-31

    Applicant: Development Center for Biotechnology ,  DCB-USA LLC ,  National Health Research Institutes

    Inventor： Shih-Chong Tsai ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Jiann-Shiun Lai ,  Chia-Cheng Wu ,  Chao-Yang Huang ,  Ya-Wei Tsai ,  Ying-Yung Lok ,  Chung-Hsiun Wu ,  Neng-Yao Shih ,  Ko-Jiunn Liu ,  Li-Tzong Chen

    IPC: A61K39/395 ,  C07K16/40 ,  A61K39/00

    CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

    Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.

    Abstract translation: 人源化抗体或其结合片段，其中所述人源化抗体结合人ENO1（GenBank：AAH50642.1），其中所述抗体包含轻链可变区（VL）结构域，其包含具有氨基酸序列LCDR1（RASENIYSYLT; SEQ ID NO：6）和具有氨基酸序列LCDR2（NAKTLPE; SEQ ID NO：7）的CDR2和具有氨基酸序列LCDR3（QHHYGTPYT; SEQ ID NO：8）和抗体重链可变区（ VH）结构域，其包含具有氨基酸序列HCDR1（GYTFTSCVMN; SEQ ID NO：3）的CDR1，具有氨基酸序列HCDR2（YINPYNDGTKYNEKFKG; SEQ ID NO：4）的CDR2和具有氨基酸序列HCDR3（EGFYYGNFDN ; SEQ ID NO：5），其中轻链可变区（VL）结构域和重链可变区（VH）结构域中的构架区包含来自人免疫球蛋白的氨基酸序列。

Patent Agency Ranking